Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 51-54

  Duan, Xinyuan ^a   Trent, John O ^a   Ye, Hong ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Structure; Sumoylation; Ubc9; Virtual screen

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE INHIBITOR; E3 LIGASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HETERODIMER; LIGASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN RAN BP2; PROTEIN UBC9; RAN GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; SUMO E1 PROTEIN; SUMO E2 PROTEIN; SUMO PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME UBC9; UBIQUITIN-CONJUGATING ENZYME UBC9;

CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENZYME SUBSTRATE; HUMAN; NONHUMAN; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; BINDING SITE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PROTEIN DOMAIN;

ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PROTEIN INTERACTION DOMAINS AND MOTIFS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 61749102005     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787047716     Document Type: Review

References (25)

1. Palancade, B.; Doye, V. Sumoylating and desumoylating enzymes at nuclear pores: underpinning their unexpected duties? Trends Cell Biol., 2008, 18, 174.
2. Baba, D.; Maita, N.; Jee, J.G.; Uchimura, Y.; Saitoh, H.; Sugasawa, K.; Hanaoka, F.; Tochio, H.; Hiroaki, H.; Shirakawa, M. Crystal structure of thymine DNA glycosylase conjugated to SUMO-1. Nature, 2005, 435, 979.
3. Geiss-Friedlander, R.; Melchior, F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol., 2007, 8, 947.
4. Johnson, E.S. Protein modification by SUMO. Annu. Rev. Biochem., 2004, 73, 355.
5. Ledl, A.; Schmidt, D.; Muller, S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene, 2005, 24, 3810.
6. McDoniels-Silvers, A.L.; Nimri, C.F.; Stoner, G.D.; Lubet, R.A.; You, M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. 2002, 8, 1127.
7. Moschos, S.J.; Smith, A.P.; Mandic, M.; Athanassiou, C.; Watson-Hurst, K.; Jukic, D.M.; Edington, H.D.; Kirkwood, J.M.;Becker, D. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene, 2007, 26, 4216.
8. Kim, J.H.; Lee, J.M.; Nam, H.J.; Choi, H.J.; Yang, J.W.; Lee, J.S.; Kim, M.H.; Kim, S.I.; Chung, C.H.; Kim, K.I.; Baek, S.H. SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 20973.
9. Mo, Y.Y.; Yu, Y.; Theodosiou, E.; Rachel Ee, P.L.; Beck, W.T. A role for Ubc9 in tumorigenesis. Oncogene, 2005, 24, 2677.
10. Kobayashi, S.; Shibata, H.; Yokota, K.; Suda, N.; Murai, A.; Kurihara, I.; Saito, I.; Saruta, T. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr. Res., 2004, 30, 617.
11. Sentis, S.; Le Romancer, M.; Bianchin, C.; Rostan, M.C.; Corbo, L Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol., 2005, 19, 2671.
12. Giraud, M.F.; Desterro, J.M.; Naismith, J.H. Structure of ubiquitinconjugating enzyme 9 displays significant differences with other ubiquitin-conjugating enzymes which may reflect its specificity for sumo rather than ubiquitin. Acta Crystallogr., 1998, 54, 891.
13. Tong, H.; Hateboer, G.; Perrakis, A.; Bernards, R.; Sixma, T.K. Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin-conjugating system. J. Biol. Chem., 1997, 272, 21381.
14. Bayer, P.; Arndt, A.; Metzger, S.; Mahajan, R.; Melchior, F.; Jaenicke, R.; Becker, J. Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol., 1998, 280.
15. Ding, H.; Xu, Y.; Chen, Q.; Dai, H.; Tang, Y.; Wu, J.; Shi, Y. Solution structure of human SUMO-3 C47S and its binding surface for Ubc9. Biochemistry, 2005, 44, 2790.
16. Huang, W.C.; Ko, T.P.; Li, S.S.; Wang, A.H. Crystal structures of the human SUMO-2 protein at 1.6 A and 1.2 A resolution: implication on the functional differences of SUMO proteins. Eur. J. Biochem., 2004, 271, 4114.
17. Reverter, D.; Lima, C.D. Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates. Nat. Str. Mol. Biol., 2006, 13, 1060.
18. Sheng, W.; Liao, X. Solution structure of a yeast ubiquitin-like protein Smt3: the role of structurally less defined sequences in protein-protein recognitions. 2002, 11, 1482.
19. Knipscheer, P.; van Dijk, W.J.; Olsen, J.V.; Mann, M.; Sixma, T.K. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. EMBO J., 2007, 26, 2797.
20. Reverter, D.; Lima, C.D. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature, 2005, 435, 687.
21. Capili, A.D.; Lima, C.D. Structure and analysis of a complex between SUMO and Ubc9 illustrates features of a conserved E2-Ubl interaction. J. Mol. Biol., 2007, 369, 608.
22. Duda, D.M.; van Waardenburg, R.C.; Borg, L.A.; McGarity, S.; Nourse, A.; Waddell, M.B.; Bjornsti, M.A.; Schulman, B.A. Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway. J. Mol. Biol., 2007, 369, 619.
23. Wang, J.; Hu, W.; Cai, S.; Lee, B.; Song, J.; Chen, Y. The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications. Mol. Cell, 2007, 27, 228.
24. Bernier-Villamor, V.; Sampson, D.A.; Matunis, M.J.; Lima, C.D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and Ran-GAP1. Cell, 2002, 108, 345.
25. Clem, B.; Telang, S.; Clem, A.; Yalcin, A.; Meier, J.; Simmons, A.; Rasku, M.A.; Arumugam, S.; Dean, W.L.; Eaton, J.; Lane, A.; Trent, J.O.; Chesney, J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther., 2008, 7, 110.